Chimerix Inc (CMRX) is a biopharmaceutical company based in Durham, North Carolina, committed to the discovery, development, and commercialization of novel, high-value therapeutic products aimed at improving the health and lives of patients worldwide. Publicly traded as CMRX, this firm is known primarily for its work in the development of antiviral medications.
Chimerix was founded in 2000, with a mission to accelerate the availability of innovative medicines, utilizing its proprietary lipid technology. Over time, it has managed to build a deep pipeline of antiviral drugs with the ability to treat various life-threatening diseases. With their deeply embedded scientific background, the team ensures they adhere to globally-accepted best practices while navigating the complex journey from drug discovery to clinical development.
One of their notable projects was the development of brincidofovir (BCV), an antiviral medication for the treatment of infections caused by double-stranded DNA viruses like cytomegalovirus (CMV) and adenovirus (AdV), which can potentially be life-threatening, especially for immunocompromised patients. Despite facing obstacle in clinical trials, the product demonstrated Chimerix's commitment to meet unmet medical needs and its resilience in dealing with clinical setbacks.
Chimerix has also been responsive to global health crises. When the deadly Ebola virus struck in West Africa in 2014, the company granted emergency use of its experimental antiviral drug, brincidofovir, to help treat patients. In 2021, Chimerix shipped TEMBEXA, a smallpox antiviral treatment, to the U.S. Strategic National Stockpile, demonstrating their commitment to global health security.
Another key asset that the company has developed is DSTAT (Dexrazoxane), a glycosaminoglycan derivative of heparin that has potential as a first-line treatment for acute myeloid leukemia (AML). Chimerix is currently testing DSTAT in a phase 3 clinical trial.
The company has managed to secure various strategic partnerships, including collaborations with other biopharmaceutical companies for research and development. Chimerix has been praised for its scientific rigor, robust pipeline, commitment to global health, and partnerships, characteristics that have assisted it in advancing its corporate agenda and achieving strategic goals.
Despite the challenges that historically come with drug discovery and development, Chimerix, Inc. (CMRX) has shown resilience and dedication to its mission. The company’s perseverance and commitment to improving lives make them a major player in the biopharmaceutical industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
The SEC has announced a settled order against Weizheng Zeng for insider trading related to Jazz Pharmaceuticals' acquisition of Chimerix. Zeng, who was involved in the due diligence for the transaction at Jazz, purchased Chimerix stock based on material nonpublic information, resulting in over $69,000 in profits. He has agreed to disgorge his profits, pay prejudgment interest, and a civil penalty without admitting or denying the SEC's findings.
Chimerix Inc. (CMRX) is trading at $8.54 intraday on NASDAQ, presenting a potential oversold bounce opportunity with key support levels at the 50-day average of $6.67 and the 200-day average of $2.75. Meyka AI rates CMRX with a score of 67 (Grade B, HOLD suggestion), projecting a 1-year price of $7.96, a 3-year price of $12.87, and a 5-year price of $17.76. The article suggests a trade plan focusing on risk control, scaling in near the 50-day average, and using partial profit targets.
The Smallpox Treatment Market report by DataM Intelligence analyzes trends, developments, and opportunities in the market, forecasting significant CAGR growth between 2024 and 2031. It highlights key players like SIGA Technologies Inc. and Bavarian Nordic A/S, segmenting the market by treatment type (antiviral, vaccines), administration route, and distribution channels. The report also provides a regional analysis and outlines its research methodology and comprehensive coverage.
Immix Biopharma has appointed Michael Grabow as Chief Commercial Officer to lead the U.S. launch and commercialization of NXC-201 for relapsed/refractory AL Amyloidosis. Grabow previously served as Senior Commercial Leader at Chimerix and brings over 25 years of biopharmaceutical commercialization experience. NXC-201, a CAR-T cell therapy, has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation (ODD) from the FDA, and Immix Biopharma believes it will be the first approved therapy for this serious and rare blood disease.
Jazz Pharmaceuticals has completed its acquisition of Chimerix Inc. for approximately $935 million, integrating Chimerix as a wholly owned subsidiary. This acquisition adds dordaviprone, a novel treatment in development for H3 K27M-mutant diffuse glioma, to Jazz's oncology portfolio, with a PDUFA action date set for August 18, 2025. The move aims to address unmet patient needs and presents a near-term commercial opportunity if dordaviprone receives FDA approval.
Chimerix (CMRX) has terminated its loan agreement with Silicon Valley Bank and requested delisting from Nasdaq following a merger where it became a wholly-owned subsidiary of a parent company. Despite facing significant financial challenges like declining revenues and persistent losses, the merger with Jazz Pharmaceuticals is seen as a positive development for strategic benefits and financial stability. Spark, TipRanks’ AI Analyst, rates CMRX as Neutral, noting strong upward momentum in technical analysis but concerns regarding valuation and profitability.